Hermann Lage

Relationship between the expression of cyclooxygenase 2 and MDR1/P-glycoprotein in invasive breast cancers and their prognostic significance.

Gene expression profiling of 30 cancer cell lines predicts resistance towards 11 anticancer drugs at clinically achieved concentrations.

Reversal of P-glycoprotein-mediated multidrug resistance in cancer cells by the c-Jun NH2-terminal kinase.

Novel three-pronged strategy to enhance cancer cell killing in glioblastoma cell lines: histone deacetylase inhibitor, chemotherapy, and oncolytic adenovirus dl520.

High antineoplastic activity of new heterocyclic compounds in cancer cells with resistance against classical DNA topoisomerase II-targeting drugs.

Potential applications of RNA interference technology in the treatment of cancer.

Analysis of gene expression profiles in melanoma cells with acquired resistance against antineoplastic drugs.

Maspin expression is characteristic for cisplatin-sensitive ovarian cancer cells and for ovarian cancer cases of longer survival rates.

CD24 expression is specific for tamoxifen-resistant ductal breast cancer cases.

MDR1/P-glycoprotein (ABCB1) as target for RNA interference-mediated reversal of multidrug resistance.

Inhibition of the multidrug-resistant phenotype by targeting YB-1 with a conditionally oncolytic adenovirus: implications for combinatorial treatment regimen with chemotherapeutic agents.

RNA interference-triggered reversal of ABCC2-dependent cisplatin resistance in human cancer cells.

A Web-based data warehouse on gene expression in human malignant melanoma.

Complete reversal of ABCG2-depending atypical multidrug resistance by RNA interference in human carcinoma cells.

ABCC2 (MRP2, cMOAT) can be localized in the nuclear membrane of ovarian carcinomas and correlates with resistance to cisplatin and clinical outcome.

CD46 expression is indicative of shorter revival-free survival for ovarian cancer patients.

Taxol-resistance-associated gene-3 (TRAG-3/CSAG2) expression is predictive for clinical outcome in ovarian carcinoma patients.

Nuclear metallothionein expression correlates with cisplatin resistance of ovarian cancer cells and poor clinical outcome.

Expression of factors involved in regulation of DNA mismatch repair- and apoptosis pathways in ovarian cancer patients.

Regulation of MDR1 gene expression in multidrug-resistant cancer cells is independent from YB-1.

Estradiol, tamoxifen and ICI 182,780 alter alpha3 and beta1 integrin expression and laminin-1 adhesion in oral squamous cell carcinoma cell cultures.

Resistance to chemotherapy in ovarian carcinoma.

Overcoming the classical multidrug resistance phenotype by adenoviral delivery of anti-MDR1 short hairpin RNAs and ribozymes.

Antineoplastic activity of 2-methoxyestradiol in human pancreatic and gastric cancer cells with different multidrug-resistant phenotypes.

Occurence of stromal myofibroblasts in the invasive ductal breast cancer tissue is an unfavourable prognostic factor.

Complete in vivo reversal of the multidrug resistance phenotype by jet-injection of anti-MDR1 short hairpin RNA-encoding plasmid DNA.

The gene polymorphism of the angiotensin I-converting enzyme correlates with tumor size and patient survival in colorectal cancer patients.

Impact of radiation therapy on the oncolytic adenovirus dl520: implications on the treatment of glioblastoma.

Three new jatrophane polyesters and antiproliferative constituents from Euphorbia tuckeyana.

Decreased expression of p16 in ovarian cancers represents an unfavourable prognostic factor.

Improved cellular pharmacokinetics and pharmacodynamics underlie the wide anticancer activity of sagopilone.

Acquired cisplatin resistance in the head-neck cancer cell line Cal27 is associated with decreased DKK1 expression and can partially be reversed by overexpression of DKK1.

Novel insight in structure-activity relationship and bioanalysis of P-glycoprotein targeting highly potent tetrakishydroxymethyl substituted 3,9-diazatetraasteranes.

Impact of novel MDR modulators on human cancer cells: reversal activities and induction studies.

Positive correlation between cyclooxygenase 2 and the expression of ABC transporters in non-small cell lung cancer.

Topoisomerase IIalpha mRNA and protein expression in ovarian carcinoma: correlation with clinicopathological factors and prognosis.

Therapeutic potential of RNA interference in drug-resistant cancers.

A prognostic gene expression index in ovarian cancer - validation across different independent data sets.

Interleukin-1 beta and tumor necrosis factor-alpha increase ABCG2 expression in MCF-7 breast carcinoma cell line and its mitoxantrone-resistant derivative, MCF-7/MX.

Comparision of the cytotoxic effects of birch bark extract, betulin and betulinic acid towards human gastric carcinoma and pancreatic carcinoma drug-sensitive and drug-resistant cell lines.

Expression of multidrug resistance-associated protein 1 in invasive ovarian carcinoma: implication for prognosis.

Influx and efflux transport as determinants of melphalan cytotoxicity: Resistance to melphalan in MDR1 overexpressing tumor cell lines.

Evaluation of microarray preprocessing algorithms based on concordance with RT-PCR in clinical samples.

Delivery of short hairpin RNAs by transkingdom RNA interference modulates the classical ABCB1-mediated multidrug-resistant phenotype of cancer cells.

Positive correlation between cyclooxygenase-2 and ABC-transporter expression in non-Hodgkin's lymphomas.

Overcoming multidrug resistance by RNA interference.

Phenolic compounds as selective antineoplasic agents against multidrug-resistant human cancer cells.

Effect of YB-1 on the regulation of micro RNA expression in drug-sensitive and drug-resistant gastric carcinoma cells.

Regulation of mRNA expression in drug-sensitive and drug-resistant gastric carcinoma cells is independent of YB-1 expression.

Jet-injection of short hairpin RNA-encoding vectors into tumor cells.

Influence of tamoxifen on cisplatin-sensitivity and estrogen receptors expression in ovarian carcinoma cell lines.

Novel structure-activity relationships and selectivity profiling of cage dimeric 1,4-dihydropyridines as multidrug resistance (MDR) modulators.

Multidrug resistance reversal properties and cytotoxic evaluation of representatives of a novel class of HIV-1 protease inhibitors.

YB-1 dependent virotherapy in combination with temozolomide as a multimodal therapy approach to eradicate malignant glioma.

Proteomic approaches for investigation of therapy resistance in cancer.

Estrogen receptor alpha expression in ovarian cancer predicts longer overall survival.

Loss of estrogen receptor beta expression correlates with shorter overall survival and lack of clinical response to chemotherapy in ovarian cancer patients.

Osteogenic potential of mesenchymal cells embedded in the provisional matrix after a 6-week healing period in augmented and non-augmented extraction sockets: an immunohistochemical prospective pilot study in humans.

Betulinic acid exhibits stronger cytotoxic activity on the normal melanocyte NHEM-neo cell line than on drug-resistant and drug-sensitive MeWo melanoma cell lines.

Healing of ungrafted and grafted extraction sockets after 12 weeks: a prospective clinical study.

CD46 Expression is an unfavorable prognostic factor in breast cancer cases.

YB-1 dependent virotherapy in combination with temozolomide as a multimodal therapy approach to eradicate malignant glioma.

Elevated YB-1 expression is a new unfavorable prognostic factor in non-Hodgkin's lymphomas.

ABCC2 (MRP2, cMOAT) Localized in the Nuclear Envelope of Breast Carcinoma Cells Correlates with Poor Clinical Outcome.

YB-1 relocates to the nucleus in adenovirus-infected cells and facilitates viral replication by inducing E2 gene expression through the E2 late promoter.

Impact of BCRP/MXR, MRP1 and MDR1/P-Glycoprotein on thermoresistant variants of atypical and classical multidrug resistant cancer cells.

Study of therapy resistance in cancer cells with functional proteome analysis.

Transport of phosphatidylserine via MDR1 (multidrug resistance 1)P-glycoprotein in a human gastric carcinoma cell line.

Modulation of the atypical multidrug-resistant phenotype by a hammerhead ribozyme directed against the ABC transporter BCRP/MXR/ABCG2.

Multiple mechanisms confer different drug-resistant phenotypes in pancreatic carcinoma cells.

Association of genomic imbalances with drug resistance and thermoresistance in human gastric carcinoma cells.

Identification of differentially expressed genes in classical and atypical multidrug-resistant gastric carcinoma cells.

Modulation of the classical multidrug resistance (MDR) phenotype by RNA interference (RNAi).

Overexpression of cMOAT (MRP2/ABCC2) is associated with decreased formation of platinum-DNA adducts and decreased G2-arrest in melanoma cells resistant to cisplatin.

Study of the development of chemoresistance in melanoma cell lines using proteome analysis.

Dynamic expression profile of p21WAF1/CIP1 and Ki-67 predicts survival in rectal carcinoma treated with preoperative radiochemotherapy.

Homozygous mutation Arg768Trp in the ABC-transporter encoding gene MRP2/cMOAT/ABCC2 causes Dubin-Johnson syndrome in a Caucasian patient.

Enhanced exposure of phosphatidylserine in human gastric carcinoma cells overexpressing the half-size ABC transporter BCRP (ABCG2).

ABC-transporters: implications on drug resistance from microorganisms to human cancers.

Reversal of breast cancer resistance protein-mediated drug resistance by tryprostatin A.

Glypican-3 is involved in cellular protection against mitoxantrone in gastric carcinoma cells.

Multidrug-resistant cancer cells facilitate E1-independent adenoviral replication: impact for cancer gene therapy.

Study of the development of thermoresistance in human pancreatic carcinoma cell lines using proteome analysis.

Molecular analysis of therapy resistance in gastric cancer.

Proteomics in cancer cell research: an analysis of therapy resistance.

RNA expression of MDR1/P-glycoprotein, DNA-topoisomerase I, and MRP2 in ovarian carcinoma patients: correlation with chemotherapeutic response.

Effective knock down of very high ABCG2 expression by a hammerhead ribozyme.

Stable and complete overcoming of MDR1/P-glycoprotein-mediated multidrug resistance in human gastric carcinoma cells by RNA interference.

Chromosomal imbalances associated with drug resistance and thermoresistance in human pancreatic carcinoma cells.

Protection of platinum-DNA adduct formation and reversal of cisplatin resistance by anti-MRP2 hammerhead ribozymes in human cancer cells.

Reversal of different drug-resistant phenotypes by an autocatalytic multitarget multiribozyme directed against the transcripts of the ABC transporters MDR1/P-gp, MRP2, and BCRP.

Overexpression of cathepsin B in gastric cancer identified by proteome analysis.

Transcriptome analysis of different multidrug-resistant gastric carcinoma cells.

Augmented expression of metallothionein and glutathione S-transferase pi as unfavourable prognostic factors in cisplatin-treated ovarian cancer patients.

Significance of cyclooxygenase 2 and MDR1/P-glycoprotein coexpression in ovarian cancers.

Prediction of doxorubicin sensitivity in breast tumors based on gene expression profiles of drug-resistant cell lines correlates with patient survival.

Prognostic value of immunohistochemical estimation of CD24 and Ki67 expression in cisplatin and paclitaxel treated ovarian carcinoma patients.